Asset Details
Do you wish to reserve the book?
PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
Do you wish to request the book?
PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
2017
Overview
Within this review we look at whether the potential provided by proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition for prevention of atherosclerotic cardiovascular disease matches the excitement generated. Two fully human monoclonal antibodies to PCSK9 are currently licenced for clinical use both in the USA and the European Union: evolocumab and alirocumab. These reduce low-density lipoprotein cholesterol by over 50% across a range of populations and were generally found to have a safety profile comparable with placebo. The development programme for a third humanised monoclonal antibody, bococizumab, was terminated early due to the presence of neutralising antibodies reducing its efficacy over time. Results from the first cardiovascular outcomes trial, FOURIER, have demonstrated significant reductions in cardiovascular events in a population with stable cardiovascular disease over a 2-year period. The ODYSSEY OUTCOMES trial comparing alirocumab to placebo is expected to report in 2018 and provide cardiovascular outcome data in a post acute coronary syndrome population. Monoclonal antibodies have an injection burden of 12–26 injections per year. An alternative approach to reducing PCSK9 is to inhibit translation of the messenger RNA for PCSK9. The phase II ORION-1 study using inclisiran, a small interference RNA to PCSK9, suggested that two doses of inclisiran produced time averaged reductions in LDL cholesterol of 50% over 9 months. The ORION-4 cardiovascular outcome trial will assess the cardiovascular benefits of two injections per year using inclisiran. With further outcome trials expected, appropriate patient selection will be key considering the higher drug costs of these therapies.
Publisher
BMJ Publishing Group LTD
Subject
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Atherosclerosis - drug therapy
/ Atherosclerosis - enzymology
/ Enzymes
/ Genes
/ Humans
/ Hypolipidemic Agents - adverse effects
/ Hypolipidemic Agents - therapeutic use
/ Lipid Metabolism - drug effects
/ Lipids
/ Mutation
/ Peptides
/ Proprotein Convertase 9 - antagonists & inhibitors
/ Proprotein Convertase 9 - genetics
/ Proprotein Convertase 9 - metabolism
/ Proteins
/ RNA, Small Interfering - therapeutic use
/ Serine Proteinase Inhibitors - adverse effects
/ Serine Proteinase Inhibitors - therapeutic use
/ Statins
